Research
Research Articles
47 research posts from BioAsset’s student analysts, each as an article. See them as slides on bioasset.info.
- The Quiet (and Growing) Giant of US Healthcare: Cardinal HealthAlay Galvankar · Company Analysis · 7 slides
Explains how drug distributor Cardinal Health earns thin margins on $254 billion in revenue and why it is growing faster than larger rival McKesson.
- Long Aktis Oncology (AKTS): Investment PitchDmitry Vysotskiy · Investment Pitch · 18 pages · PDF
The pitch recommends buying Aktis Oncology (AKTS), a clinical-stage developer of miniprotein radiopharmaceuticals for solid tumors.
- The FDA has approved Takeda’s oveporexton, the first orexin agonist for narcolepsyJoy Wu · FDA Approval · 5 slides
The FDA has approved Takeda’s oveporexton, the first orexin agonist for narcolepsy, and drugmakers see wider uses for the orexin pathway.
- Designer-ish Babies: Will it be the Future?Jingqiu Tian · Industry Trends · 7 slides
Looks at startups such as Nucleus Genomics that screen IVF embryos for disease risk and traits like height and IQ, and the ethical debate around them.
- FDA Approves Rasonque: The First RAS-Targeted Drug for Pancreatic CancerNeev Mohindroo · FDA Approval · 4 slides
The FDA has approved Rasonque, the first RAS-targeted drug for pancreatic cancer, a once-daily pill priced at $477,000 a year.
- The Parkinson’s Bet That Couldn’t Hold $15: Aspen Neuroscience’s IPOJudy Dalati · Company Analysis · 5 slides
Aspen Neuroscience raised $140.6 million in its IPO for a Parkinson’s cell therapy, then fell about 17% below its $15 IPO price within two weeks.
- A $1.3B Bet: Merck KGaA Buys Silence TherapeuticsViren Jain · Company Analysis · 5 slides
Merck KGaA agreed to buy Silence Therapeutics for about $1.3 billion, a 130% premium, to gain divesiran, an unapproved siRNA drug for a rare blood cancer.
- From the Space Race to the Biotech Race: China Guards Its LeadJudy Dalati · Industry Trends · 5 slides
China proposed blocking foreign acquisitions of its cell and gene therapy and siRNA platforms, protecting a growing lead in early-stage drug development.
- The Shovel Sellers of AI Biology: Twist BioscienceNeev Mohindroo · Company Analysis · 5 slides
Twist Bioscience rose 16% to $184 after Leerink named it the top beneficiary of Anthropic’s biology push, because every AI-designed protein still has to be built from DNA.
- The Price to Pay to End an mRNA Vaccine Fight: Up to $2.25B to be Paid by ModernaJingqiu Tian · Company Analysis · 5 slides
Moderna will pay up to $2.25 billion to Arbutus and Genevant to settle a patent dispute over the lipid nanoparticles used in its mRNA vaccines.
- $6.7B: Merck’s Leukemia Drug Acquisition That Could Shake Up The MarketAlay Galvankar · Company Analysis · 5 slides
Merck is buying Terns Pharmaceuticals for about $6.7 billion to gain TERN-701, an oral leukemia drug that would compete with Novartis’ Scemblix.
- UK Biobank: Turning Biological Data into Drug DiscoveryBrendan Seo · Deep Dive · 5 slides
Explains how UK Biobank’s health, genetic and lifestyle data from over 500,000 participants supports early-stage drug discovery.
- Saliva, Stress, and Startups: The Rise of Cortisol TestingJoy Wu · Industry Trends · 5 slides
Covers the rise of saliva-based cortisol testing, including how it differs from blood tests, the lab methods behind it and the startups involved.
- Tectonic Therapeutic (TECX): Long Thesis Memo & Financial ModelBenjamin Shar · Memo + Model · 12 pages · PDF + XLSX
The memo recommends a long position in Tectonic Therapeutic (TECX), arguing its relaxin drug TX45 is mispriced after rival program failures.
- CRISPR’s Fatal Test: Intellia’s In-Vivo Reality CheckDmitry Vysotskiy · 4 slides
Intellia paused a Phase III in vivo CRISPR trial after a patient death and the FDA placed a clinical hold, raising safety questions for gene editing.
- $11 Insulin: California Rewrites the Prescription on Big PharmaDmitry Vysotskiy · 4 slides
California’s CalRx will sell long-acting insulin pens for about $11 each from January 1, 2026, challenging major insulin makers on price.
- Roche Pill Delays Tumor Progression in Closely Watched Breast Cancer StudyDmitry Vysotskiy · 5 slides
Roche’s giredestrant plus everolimus cut the risk of breast cancer progression by about 62% in ESR1-mutated patients in the Phase 3 evERA trial.
- Blackstone x TPG Make Hologic Private ($18.3B)Dmitry Vysotskiy · 4 slides
Blackstone and TPG will take women’s health med-tech company Hologic private in a deal valued at up to $18.3 billion.
- Inside China’s Transformative Global Biotech BoomDmitry Vysotskiy · 4 slides
Describes how Chinese biotech firms are moving from generic production to global drug innovation and licensing deals with Western pharma.
- The $30 Million Bet: How Valthos and AI Are Rewriting BiodefenseDmitry Vysotskiy · 4 slides
OpenAI Startup Fund, Lux Capital and Founders Fund backed Valthos with $30 million to build AI systems for detecting and countering biological threats.
- Eli Lilly vs Novo Nordisk: Who Will Win the GLP-1 Race?Dmitry Vysotskiy · 5 slides
Compares Eli Lilly and Novo Nordisk in the GLP-1 market, focusing on the race to bring an effective oral weight-loss pill to patients.
- From Chips to Clinics: Nvidia Expands Its Healthcare AmbitionsDmitry Vysotskiy · 5 slides
Nvidia is expanding into healthcare through AI partnerships with Eli Lilly, Verily, Johnson & Johnson, Innovaccer and the Chan Zuckerberg Initiative.
- Breaking Bones: Inside J&J’s Orthopedics SpinoffDmitry Vysotskiy · 5 slides
Johnson & Johnson plans to spin off its orthopedics business as a standalone company, DePuy Synthes, within 18 to 24 months.
- From One Drop to Fifty Diagnoses: How Blood May Be the Next Frontier of Cancer DetectionDmitry Vysotskiy · 5 slides
GRAIL’s blood test detected signals for more than 50 cancer types in a trial of over 23,000 symptom-free adults, often at early stages.
- Biotech X Beauty: The Future of SkincareDmitry Vysotskiy · 5 slides
Covers biotech-derived skincare, including polynucleotide therapy, personalized products and Debut’s $20 million raise for AI ingredient discovery.
- America’s GLP-1 Paradox: Obesity Falls, Diabetes RisesDmitry Vysotskiy · 5 slides
Gallup data show US adult obesity falling to 37.0% in 2025 as GLP-1 drug use rises, while diabetes diagnoses keep climbing.
- AI’s Early Footprint: Optimized Peptides for Efficient Protein ProductionDmitry Vysotskiy · 5 slides
Researchers at Nagoya University used AI to find four-amino-acid peptide tags that prevent ribosome stalling and raise protein yields in E. coli.
- BioAsset VC Dive: Predict Before You Test — Axiom and AI ToxicologyDmitry Vysotskiy · 5 slides
Profiles Axiom, a seed-stage San Francisco startup building AI models to predict drug liver toxicity in place of animal testing.
- AI x Drug Discovery: From Computation To CureDmitry Vysotskiy · 4 slides
Reviews how AI is being used in drug discovery, with examples from Insilico Medicine, Variant Bio, GSK and AstraZeneca.
- BioAsset Autopsies: The Intarcia StoryDmitry Vysotskiy · 5 slides
Examines why Intarcia Therapeutics collapsed after raising $1.9 billion for its ITCA 650 diabetes implant and receiving two FDA rejections.
- BioAsset Weekly: The Pricing Wars, Regulation and M&ADmitry Vysotskiy · 5 slides
Covers the TrumpRx.gov launch, the Novo Nordisk and Eli Lilly outlook, FDA pressure on Hims & Hers, and GSK’s purchase of Rapt Therapeutics.
- Update: Revolution MedicinesBrendan Seo · 1 slide
Revolution Medicines reported positive Phase 3 data for daraxonrasib in metastatic pancreatic cancer at the 2026 ASCO Annual Meeting.
- Parasites as Biotech Assets: From Disease to Drug DiscoveryBrendan Seo · 5 slides
Explains how molecules that parasites use to evade the immune system are being studied as starting points for autoimmune and cancer drugs.
- Replimune’s Stock Crash After FDA RejectionBrendan Seo · 5 slides
Replimune’s stock fell about 19% in one session after the FDA again rejected its cancer therapy for insufficient evidence of effectiveness.
- Atavistik Bio: $160M to Drug the Undruggable and Cure a Rare Blood DisorderJingqiu Tian · 5 slides
Atavistik Bio has raised $160 million in Series B funding to develop allosteric drugs, led by ATV-1601 for the bleeding disorder HHT.
- Alternative Prostate Cancer Treatment: Targeting Thyroid Hormone ReceptorsJingqiu Tian · 5 slides
A 2025 paper suggests blocking a thyroid hormone receptor with the compound NH-3 could treat prostate cancer that resists androgen therapy.
- Treating the Impossible: Novel Treatments Potentially Curing Type 1 DiabetesJingqiu Tian · 5 slides
Surveys recent type 1 diabetes treatments, from the antibody teplizumab to stem cell-derived islet transplants and gene editing.
- Update: BMS x AnthropicAlay Galvankar · 1 slide
Bristol Myers Squibb struck a deal with Anthropic to roll out Claude to more than 30,000 employees across the company.
- Growth: Radioisotope Supply BoostAlay Galvankar · 1 slide
Niowave has broken ground on a $75 million Actinium-225 production facility in Lansing, Michigan, expected to come online in 2028.
- Update: Replimune Stock SurgesAlay Galvankar · 1 slide
Replimune shares rose over 90% after the company aligned with the FDA on a path to resubmit its application for RP1.
- Novo X Hims: From Lawsuit to Partnership — What It Means for GLP-1Alay Galvankar · 5 slides
Novo Nordisk dropped its lawsuit against Hims & Hers and struck a deal for Hims to sell Novo’s branded GLP-1 medicines on its platform.
- Fast-Tracked: How Hernexeos Won FDA Approval in 44 DaysAlay Galvankar · 5 slides
Boehringer Ingelheim’s lung cancer pill Hernexeos won FDA approval 44 days after receiving a national priority voucher under the CNPV program.
- BioAsset VC Dive: Xaira Therapeutics — Can AI Crack the Drug Discovery Code?Alay Galvankar · 5 slides
Profiles Xaira Therapeutics, an AI-native drug discovery company founded in 2024 that launched with more than $1 billion in capital.
- Regeneron x CytomXNeev Mohindroo · 5 slides
Regeneron expanded its collaboration with CytomX in a licensing deal worth $37 million upfront and up to $4 billion in milestones.
- Lilly NeuroscienceNeev Mohindroo · 5 slides
Eli Lilly expanded in neuroscience by acquiring Centessa for up to $7.8 billion and partnering with BioArctic on brain drug delivery.
- All Eyes On Cancer TherapySharath Venkatesan · 1 slide
The 2026 ASCO Annual Meeting opened in Chicago with attention on Revolution Medicines’ pipeline and bispecific antibodies.
- The Cost of Uncertainty: uniQure’s Battle with the FDASharath Venkatesan · 6 slides
uniQure’s Huntington’s gene therapy AMT-130 was set back when the FDA reversed prior guidance and demanded a Phase 3 trial before filing.